Source: CureToday articles
The dual-targeting CAR T-cell therapy KITE-363 showed positive response rates and manageable side effects in relapsed or refractory B-cell lymphoma.
Recent Content
- Utilizing AI in Prostate Cancer Care and Management
- KITE-363 Shows High Response in B-Cell Lymphoma With Manageable Safety
- Rilonacept in Recurrent Pericarditis: Mechanism of Action, Patient Management, and Clinical Considerations
- Zyprexa Added to Standard Antiemetics Reduces Nausea, Vomiting in Radiation
- Op-Ed: Expand Patient Choice to Lower Medication Costs
- Sasanlimab-BCG Combo May Delay Recurrence in Bladder Cancer
- Meta-Analysis Evaluates RSV Viral Load and Symptom Kinetics
- Personalized Vaccine Elicits Responses in Patients With Kidney Cancer
- SCIg More Effective Immunoglobulin Option for Immunocompromised Patients With Inborn Errors of Immunity
- GLP-1 Receptor Agonists Demonstrate Increased Risk of Neovascular Age-Related Macular Degeneration in Diabetes